A well-supplied UK & EU sector, led by PRINTING HOUSE LTD, most recent listing 13 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
This publication is about entering into non-exclusive discount contracts according to § 130c Abs. 1 SGB V in conjunction with § 130a Abs. 8 SGB V for finished medicinal products containing the active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57) as part of an "open-house model". Under unif
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Axitinib (ATC: L01EK01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical product Somatropin, classified under ATC code H01AC01. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into contracts at any time during this perio
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Denosumab, marketed as Xgeva, in accordance with German social law. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into agreements at any
This announcement is not for the awarding of a public contract as defined by the Public Procurement Directive (2014/24/EU) or competition law. It aims to inform interested pharmaceutical companies broadly and is published in the Supplement to the Official Journal of the European Union. The term 'Ope
The KKH (Kaufmännische Krankenkasse) aims to establish non-exclusive discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process allows all eligible and interested pharmaceutical companies
The Kaufmännische Krankenkasse (KKH) aims to establish discount agreements with all suitable pharmaceutical companies for the active ingredient(s) under Section 130a (8) of the Social Code Book V (SGB V) through an 'Open-House' procedure. This process allows all eligible and interested pharmaceutica
The Kaufmännische Krankenkasse (KKH) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under Section 130a (8) of the Social Code Book V, using an 'Open-House' procedure. This process allows all eligible and interested pharmaceutical
The KKH (Kaufmännische Krankenkasse) aims to establish discount agreements with all suitable pharmaceutical companies for the active ingredient(s) under Section 130a, Paragraph 8 of the Social Code Book V, through an 'Open-House' procedure. This process allows all eligible and interested pharmaceuti
This contract opportunity involves the establishment of non-exclusive discount agreements for the drug Trastuzumab, classified under ATC code L01FD01, in the regions of Lower Saxony, Bremen, and Saxony-Anhalt. The focus is on parenteral preparations made from finished medicinal products for oncology
